Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Pegvisomant treatment in a 4-year-old girl with neurofibromatosis type 1

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Aortic dimensions in girls and young women with Turner syndrome - a magnetic resonance imaging study

    Research output: Contribution to journalConference articleResearchpeer-review

  2. Low birth weight and male reproductive function

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Metabolic aspects of insulin resistance in individuals born small for gestational age

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Insulin-like growth factor I (IGF-I) and IGF-binding protein 3 as diagnostic markers of growth hormone deficiency in infancy

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Hippocampal volume, cognitive functions, depression, anxiety, and quality of life in patients with Cushing's syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: a longitudinal cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Populations, decreasing fertility, and reproductive health

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Cerebral infarction after fractionated stereotactic radiation therapy of benign anterior skull base tumors

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND/AIMS: Growth hormone (GH) excess in childhood is a rare disorder. Current treatment options such as somatostatin analogues, pituitary surgery or irradiation can have serious side effects. Recently, a GH receptor antagonist, pegvisomant, was introduced for the treatment of adults with acromegaly. We wanted to investigate whether pegvisomant was effective in a child with octreotide-resistant GH excess.

CASE: A 4-year-old girl with neurofibromatosis type 1 and GH excess associated with optic glioma received pegvisomant injections (10 mg subcutaneously) with increasing intervals from daily to every 4th day.

RESULTS: IGF-I and IGFBP-3 decreased from +6.9 and 4.6 standard deviation scores (SDS), respectively, to within normal range. Height velocity dropped from 12.4 SDS to mean -0.7 SDS (range: -5.0 to 5.0) and height SDS decreased from +1.3 to +0.6 (target height: +0.2). Random non-fasting serum GH values were mean 5.0 mlU/l (range: 1.6-9.5). There was no change in fasting blood glucose (4.6-4.7 mmol/l) or glycosylated haemoglobin (5.5%) and no subjective or biochemical side effects. Repeated tests of thyroid, adrenal and gonadal function showed no alterations during the treatment period. Intracranial tumours remained unchanged in size and visual impairment did not deteriorate.

CONCLUSION: Pegvisomant normalized IGF-I and IGFBP-3 levels. Growth velocity was normalized after initial catch-down growth, and it remains to be seen whether this result can be maintained during long-term treatment.

Original languageEnglish
JournalHormone Research
Volume65
Issue number1
Pages (from-to)1-5
Number of pages5
ISSN0301-0163
DOIs
Publication statusPublished - 2006

    Research areas

  • Antineoplastic Agents, Body Height, Child, Preschool, Female, Human Growth Hormone, Humans, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor I, Neurofibromatosis 1, Optic Nerve Glioma, Case Reports, Journal Article

ID: 51497098